+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route of Administration, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011655
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Rheumatology Therapeutics Market grew from USD 33.24 billion in 2024 to USD 35.45 billion in 2025. It is expected to continue growing at a CAGR of 6.54%, reaching USD 48.62 billion by 2030.

Setting the Stage for a New Era in Rheumatology Therapies

Rheumatology therapeutics have entered a pivotal chapter marked by unprecedented innovation, shifting policy landscapes, and evolving patient expectations. This executive summary distills a complex mosaic of scientific advancements, regulatory adjustments, and market dynamics into a strategic narrative designed for decision-makers seeking clarity amidst rapid change. By examining breakthroughs in drug development alongside the implications of new trade policies and nuanced segmentation analyses, readers will gain an integrated perspective on the forces shaping the future of patient care.

Drawing from rigorous primary and secondary research, this summary highlights the critical drivers and barriers that define the competitive terrain. Whether your organization is exploring novel molecular targets or reassessing distribution strategies, the insights presented here offer a cohesive framework for informed strategic planning. As you navigate these transformative shifts, the perspectives consolidated in this summary will serve as a compass for allocating resources and prioritizing initiatives in the global rheumatology sector.

Unveiling Pivotal Shifts Reshaping the Therapeutic Landscape

The rheumatology landscape is experiencing transformative shifts driven by technological innovation and a heightened focus on personalized care. Advances in genomic profiling and biomarker discovery have accelerated the development of targeted therapeutics, enabling interventions that address the underlying mechanisms of autoimmune inflammation rather than merely alleviating symptoms. Furthermore, digital health solutions such as remote patient monitoring and telemedicine are redefining treatment paradigms, fostering continuous engagement and adherence through real-time data insights.

Regulatory authorities have responded to these innovations by streamlining approval pathways and incentivizing novel modalities, particularly in cell-based and gene therapies. Meanwhile, healthcare payers are embracing value-based reimbursement models that reward measurable patient outcomes. This alignment between regulatory flexibility, payer demands, and technological capability is catalyzing a shift from broad-spectrum immunosuppression toward precision medicine approaches tailored to individual patient profiles.

Assessing the Ripple Effects of 2025 Tariff Adjustments on US Market Dynamics

The introduction of new tariffs on imported active pharmaceutical ingredients and finished formulations has reshaped cost structures and supply-chain configurations since 2025. Manufacturers have encountered increased input cost volatility, leading some to reassess global sourcing strategies and explore near-shoring opportunities to mitigate tariff exposure. These adjustments have prompted parallel negotiations with contract development and manufacturing organizations to secure more favorable terms and ensure continuity of supply.

Moreover, payers and providers have felt the pressure of rising drug acquisition costs, resulting in tighter formulary management and more stringent reimbursement criteria. In response, innovators have accelerated the pursuit of cost-containment measures such as process optimization and strategic partnerships across the value chain. As a result, organizations that proactively adapt to this new tariff environment by diversifying supplier networks and enhancing operational resilience are better positioned to maintain competitive pricing and patient access.

Decoding Market Dynamics Through Comprehensive Segmentation Analysis

An in-depth segmentation analysis reveals differentiated growth trajectories across therapeutic classes, molecule types, indications, routes of administration, distribution channels, and patient age groups. Within therapeutic classes, the landscape is anchored by Conventional DMARDs, IL-6 inhibitors, JAK inhibitors, and TNF inhibitors. Conventional DMARDs continue to hold a foundational position, with hydroxychloroquine, leflunomide, methotrexate, and sulfasalazine maintaining steady utilization owing to their established efficacy and cost advantages.

When considering molecule type, biologics remain at the forefront of innovation, driven by enhanced specificity and efficacy profiles. Simultaneously, biosimilars are gaining traction as cost-effective alternatives, fostering competitive pricing dynamics and broader patient access. Small molecules persist as essential components of treatment regimens, particularly when oral administration aligns with patient preferences and adherence requirements.

Indication-based insights highlight that rheumatoid arthritis continues to represent the largest segment, followed by psoriatic arthritis and ankylosing spondylitis. Growing recognition of gout management and evolving treatment protocols for systemic lupus erythematosus signal emerging opportunities for targeted interventions. This indication mix underscores the importance of therapeutic differentiation and tailored clinical trial designs to address distinct pathophysiologies.

The route of administration analysis demonstrates a persistent preference for oral therapies, driven by patient convenience and reduced clinical resource utilization. Nonetheless, subcutaneous and intravenous formulations remain integral for biologic delivery, with innovations in self-administration devices enhancing patient autonomy. Distribution channel dynamics reveal that hospital pharmacies continue to be key nodes for specialized therapies, while online and retail pharmacies are increasingly leveraged to improve accessibility and streamline refill processes.

Age group segmentation underscores a bifurcation between adult and pediatric cohorts. Adult patients dominate market volumes, yet pediatric indications are witnessing greater clinical focus and investment as manufacturers seek to expand labeled indications. Tailoring formulations and dosing regimens for younger populations contributes to comprehensive lifecycle management strategies.

Unlocking Regional Nuances Driving Global Market Performance

Regional performance exhibits distinctive trends shaped by economic maturity, healthcare infrastructure, and policy frameworks. In the Americas, market growth is driven by robust R&D investment, favorable patent protections, and well-established distribution networks. The United States leads in innovative pipeline launches, while Latin American markets are embracing biosimilars to manage budget constraints and improve treatment affordability.

Europe, the Middle East, and Africa present a mosaic of market conditions. Western European countries benefit from consolidated healthcare systems and progressive reimbursement schemes, facilitating early adoption of high-cost therapies. In contrast, certain markets in the Middle East and Africa are at nascent stages of biologic uptake, hindered by infrastructure limitations and variable regulatory convergence. Strategic collaborations and technology transfers are emerging as key enablers for expanding access in these regions.

Asia-Pacific is characterized by rapid market expansion underpinned by growing healthcare expenditure and a rising prevalence of autoimmune disorders. Markets such as Japan and South Korea exhibit high uptake of advanced therapeutics supported by strong local manufacturing capabilities. Meanwhile, emerging economies in Southeast Asia and India are leveraging biosimilars to broaden patient reach, with government initiatives increasingly focused on strengthening regulatory harmonization and pharmacovigilance frameworks.

Profiling Industry Leaders Shaping Competitive Advantage

Leading pharmaceutical and biotechnology companies are reinforcing their competitive positions through diversified pipelines, strategic alliances, and targeted acquisitions. Biologics pioneers continue to invest in next-generation IL-6 and JAK inhibitor portfolios, leveraging clinical trial successes to extend market exclusivity. At the same time, biosimilar developers are scaling production capacity and pursuing multi-region approvals to capitalize on patent expirations and cost-containment pressures.

Strategic partnerships between mid-sized innovators and large commercial entities have accelerated late-stage development of novel therapies, while collaborations with academic centers are fueling translational research efforts. Companies are increasingly embedding real-world evidence generation into their development programs to substantiate value propositions during payer negotiations. Moreover, M&A activity has centered on acquiring niche capabilities in areas such as companion diagnostics, digital adherence tools, and formulation technologies, underlining the importance of integrated solutions in driving differentiation.

Strategic Blueprint for Accelerating Market Leadership

To navigate this evolving landscape and secure leadership, organizations should prioritize investment in precision medicine platforms that integrate genomic, proteomic, and digital health data streams. Establishing cross-functional teams tasked with delivering comprehensive outcomes studies will strengthen value-based contracting discussions. Furthermore, diversifying portfolios through both in-house innovation and strategic licensing agreements can mitigate pipeline concentration risk and unlock new therapeutic niches.

Operationally, companies must enhance supply-chain agility by building regional manufacturing hubs and forging resilient supplier partnerships. Digital engagement initiatives, such as patient support apps and virtual nurse programs, should be expanded to enhance adherence and gather real-world insights. Finally, forging alliances with payers and patient advocacy groups will be critical to co-creating value frameworks that address affordability and access imperatives while sustaining revenue objectives.

Rigorous Methodological Framework Underpinning Market Insights

This analysis integrates a dual-track research methodology combining comprehensive secondary data reviews with targeted primary interviews. Secondary sources encompassed peer-reviewed literature, regulatory filings, clinical trial registries, and proprietary databases, providing a quantitative foundation. Complementing this, structured interviews with key opinion leaders, payers, industry executives, and patient advocates yielded qualitative perspectives on market drivers, challenges, and emerging trends.

Data triangulation ensured alignment between quantitative metrics and stakeholder insights, with discrepancies resolved through follow-up consultations. Geographic representation spanned major markets across the Americas, Europe, Middle East, Africa, and Asia-Pacific, ensuring global applicability. All findings underwent rigorous validation protocols, including cross-verification with published benchmarks and expert review panels, to guarantee accuracy and relevance.

Consolidating Insights to Chart the Future of Rheumatology Therapeutics

The insights presented herein crystallize the intersection of scientific innovation, policy evolution, and market strategy, offering a holistic perspective on the rheumatology therapeutics ecosystem. By synthesizing segmentation analyses, regional dynamics, and competitive positioning, this summary equips stakeholders with actionable intelligence to guide strategic priorities. As the market continues to evolve, organizations that embrace data-driven decision making and foster collaborative partnerships will be best positioned to deliver transformative patient outcomes and sustainable growth.

In an era defined by precision medicine and value-centric care models, the imperative is clear: leverage these insights to anticipate shifts, optimize resource allocation, and capitalize on emerging opportunities in rheumatology.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Class
    • Conventional Dmards
      • Hydroxychloroquine
      • Leflunomide
      • Methotrexate
      • Sulfasalazine
    • Il-6 Inhibitors
    • Jak Inhibitors
    • Tnf Inhibitors
  • Molecule Type
    • Biologics
    • Biosimilars
    • Small Molecules
  • Indication
    • Ankylosing Spondylitis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Route Of Administration
    • Intravenous
    • Oral
    • Subcutaneous
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Patient Age Group
    • Adult
    • Pediatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Roche Holding AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • UCB S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Rheumatology Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Conventional Dmards
8.2.1. Hydroxychloroquine
8.2.2. Leflunomide
8.2.3. Methotrexate
8.2.4. Sulfasalazine
8.3. Il-6 Inhibitors
8.4. Jak Inhibitors
8.5. Tnf Inhibitors
9. Rheumatology Therapeutics Market, by Molecule Type
9.1. Introduction
9.2. Biologics
9.3. Biosimilars
9.4. Small Molecules
10. Rheumatology Therapeutics Market, by Indication
10.1. Introduction
10.2. Ankylosing Spondylitis
10.3. Gout
10.4. Psoriatic Arthritis
10.5. Rheumatoid Arthritis
10.6. Systemic Lupus Erythematosus
11. Rheumatology Therapeutics Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
11.4. Subcutaneous
12. Rheumatology Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.3. Online Pharmacy
12.4. Retail Pharmacy
13. Rheumatology Therapeutics Market, by Patient Age Group
13.1. Introduction
13.2. Adult
13.3. Pediatric
14. Americas Rheumatology Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Rheumatology Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Rheumatology Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. Johnson & Johnson
17.3.3. Novartis AG
17.3.4. Roche Holding AG
17.3.5. Pfizer Inc.
17.3.6. Amgen Inc.
17.3.7. Eli Lilly and Company
17.3.8. Sanofi S.A.
17.3.9. Bristol-Myers Squibb Company
17.3.10. UCB S.A.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. RHEUMATOLOGY THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. RHEUMATOLOGY THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. RHEUMATOLOGY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY LEFLUNOMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SULFASALAZINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 53. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 54. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 55. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 59. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 65. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 97. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 98. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 101. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 105. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 106. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 117. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 118. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 119. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 120. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 121. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 125. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 126. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 127. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 149. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 151. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 152. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 153. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 154. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 155. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 156. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 157. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 167. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 168. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 169. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 172. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 174. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 175. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 176. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 177. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 194. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 196. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 197. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 202. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 203. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 204. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 212. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 215. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 216. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 217. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 218. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 221. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 223. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 224. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 225. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 226. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 235. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 242. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 243. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 244. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 245. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 246. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 247. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 248. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 250. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 251. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 252. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 253. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 254. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 255. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 257. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 258. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 260. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 261. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 262. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 278. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 286. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 287. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 288. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 289. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 290. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 291. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 297. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 299. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 304. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 311. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 312. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY

Companies Mentioned

The companies profiled in this Rheumatology Therapeutics market report include:
  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Roche Holding AG
  • Pfizer Inc.
  • Amgen Inc.
  • Eli Lilly and Company
  • Sanofi S.A.
  • Bristol-Myers Squibb Company
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 35.45 Billion
Forecasted Market Value ( USD ) by 2030 $ 48.62 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Rheumatology Therapeutics - Global Strategic Business Report - Product Image

Rheumatology Therapeutics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From
Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Rheumatology Therapeutics Market Report 2025 - Product Image

Rheumatology Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anti-Rheumatics Market Report by Type, Route of Drug Administration, Distribution Channel, and Region 2024-2032 - Product Image

Anti-Rheumatics Market Report by Type, Route of Drug Administration, Distribution Channel, and Region 2024-2032

  • Report
  • 140 Pages
  • Global
From
Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030 - Product Image

Anti-Rheumatics Market by Drug Class (Corticosteroids, Disease Modifying Anti-rheumatics Drugs, Nonsteroidal Anti-inflammatory Drugs), Route Of Administration (Injectable, Oral, Topical), Type, Disease Type, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From

About the Anti Rheumatic Market

The Anti Rheumatic market is a subset of the Immune Disorders Drugs market, which focuses on the treatment of rheumatic diseases. These diseases are caused by an abnormal immune response, which can lead to inflammation and joint pain. Anti Rheumatic drugs are used to reduce inflammation and pain, as well as to prevent further damage to the joints. These drugs can be administered orally, intravenously, or topically. Commonly used Anti Rheumatic drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and biologic response modifiers. Some companies in the Anti Rheumatic market include AbbVie, Amgen, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.